ENDRA Life Sciences

ENDRA Life Sciences

Health Care Equipment & Supplies
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

$9.1M

Market Cap • 10/2/2026

2007

(19 years)

Founded

2017

(9 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

1,4

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

4,2

EPS

—

Market Cap

Market Cap

9,1M

EV

7,8M

EV/Revenue

0

EV/EBITDA

-1,2

EV/EBIT

-1,2

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-48,1%

Total Yield

-48,1%

Payout

0%

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

48,4%

Capex/OCF

-0,4%

SBC/OCF

—

% PPE

5,6%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

-10%

CAGR Net Income 5Y

-11,6%

CAGR OCF 5Y

-13,4%

Leverage

N.D./EBITDA

0,2

Debt/Equity

0%

Current Ratio

40,3

Quick Ratio

12,5

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium